Device profile of the Vici venous stent for chronic iliofemoral venous obstruction recanalization: overview of its safety and efficacy

ABSTRACT

Introduction: Endovenous stenting is being increasingly used for the management of iliofemoral venous outflow obstruction due to thrombotic or non-thrombotic iliac vein lesions (NIVL). Dedicated venous stents have replaced re-purposed arterial stents but there are limited data on their relative safety and efficacy.

Areas covered: This review looks at the available literature on the safety and efficacy of the Veniti Vici Venous stent (Boston Scientific), a specific venous stent, and compares its outcomes with the other venous stents that are currently available. Reported outcomes include patency, clinical efficacy, and the number of adverse events.

Expert opinion: The initial clinical trials of the Vici venous stent have shown both good clinical and safety outcomes at 12–24 months follow-up. Longer follow-up data are pending and further trials comparing available stents are required. Current evidence supports its use in the management of deep venous reconstruction, especially in occlusive post-thrombotic disease. Patients should, however, be made aware of the paucity of long-term data and the need for monitoring within a dedicated surveillance program following stent placement.

KEYWORDS:

• Deep vein thrombosis
• venous stent
• endovascular surgery
• post thrombotic syndrome
• Stent
• venous reconstruction

Article Highlights

• The Vici Venous Stent is a venous specific, self-expandable, closed-cell, nickel-titanium (nitinol) stent.

• It is the only closed-cell system venous stent currently available designed to provide improved crush resistance to external forces compared with open-cell designs.

• Current evidence supports the use of the Vici Venous Stent in the management of deep venous reconstruction, especially in occlusive post-thrombotic disease.

• Clinical and quality of life outcomes appear improved in the short-term following stent placement and it is associated with a low incidence of major adverse events.

• Further investigations are required, with long-term follow-up to determine the durability of the Vici stent and whether there are differences in performance between patient groups, types of stent used (open versus closed cell) and when placed below the inguinal ligament.

Declaration of Interest

S Black has received consulting and speaker fees for - Cook, Bard, Gore, Boston Scientific, Philips-Volcano, Medtronic, and Optimed. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.